

Numarul de pacienti eligibili comunicati de comisiile de specialitate ale Ministerului Sanatatii, pentru fiecare terapie in parte aferenta medicamentelor pentru care s-a emis Deciziei de includere conditionata in Lista si pentru care detinatorii de autorizatii de punere pe piata prin reprezentantii lor legali au depus la CNAS cererea prin care isi exprima disponibilitatea pentru inceperea procesului de negociere a contractelor cost-volum/cost- volum -rezultat - situatie actualizata la data de 31.08.2015

| Nr. crt. | DAPP | NR PAC ELIGIBILI comunicat de comisiile de specialitate ale MS, prin adresa NB4469/2015* si AIT44934/2015 | DECIZIE AMNDM DE INCLUDERE CONDITIONATA NR./DATA | DATA TRANSMITERII DE ANMDM A DECIZIEI LA CNAS | MEDICAMENT DCI | MEDICAMENT DENUMIRE COMERCIALA | FORMA FARMACEUTICA | CONCENTRATIE |
|----------|---|---|--|---|----------------|--------------------------------|---------------------------|----------------------------|
| 1 | JANSSEN CILAG INTERNATIONAL NV | 1100 din care 550 alocati specific acestui medicament de comisia oncologie | 320 / 20.04.2015 | 06.05.2015 | ABIRATERONUM | ZYTIGA | COMP. | 250 mg |
| 2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 350(comisia oncologie) | 327 / 20.04.2015 | 28.04.2015 | AFATINIBUM | GIOTRIF | COMP. FILM. | 20 mg; 30 mg; 40 mg; 50 mg |
| 3 | BAYER PHARMA AG | 0 (comisia oftalmologie) | 343 / 20.04.2015 | 28.04.2015 | AFLIBERCEPTUM | EYLEA | SOL. INJ. | 40 mg/ml |
| 4 | BAYER PHARMA AG | 0 (comisia oftalmologie) | 332 / 20.04.2015 | 28.04.2015 | AFLIBERCEPTUM | EYLEA | SOL. INJ. | 40 mg/ml |
| 5 | SANOFI - AVENTIS GROUPE | 750 (comisia oncologie) | 312 / 20.04.2015 | 28.04.2015 | AFLIBERCEPTUM | ZALTRAP | CONCENTRAT PT. SOL. PERF. | 25 mg; 100 mg; 200 mg |
| 6 | BRISTOL - MYERS SQUIBB/PFIZER EEIG | 12 500(comisia ortopedie) | 342 / 20.04.2015 | 28.04.2015 | APIXABANUM | ELIQUIS | COMP. FILM. | 5 mg |
| 7 | BRISTOL - MYERS SQUIBB/PFIZER EEIG | 12 500(comisia ortopedie) | 341 / 20.04.2015 | 28.04.2015 | APIXABANUM | ELIQUIS | COMP. FILM. | 2,5 mg |
| 8 | EVER NEURO PHARMA GMBH | | 348 / 20.04.2015 | 28.04.2015 | APOMORFINUM | DACEPTON | SOL. INJ. / PERF. | 10 mg/ml |
| 9 | PFIZER LIMITED | 400 (comisia oncologie) | 345 / 20.04.2015 | 28.04.2015 | AXITINIB | INLYTA | COMP. FILM. | 1 mg, 5mg |
| 10 | MERCK SHARP & DOHME | 0(comisia gastroenterologie) | 310 / 20.04.2015 | 28.04.2015 | BOCEPREVIRUM | VICTRELIS | CAPSULE | 200 mg |

| Nr. crt. | DAPP | NR PAC ELIGIBILI comunicat de comisiile de specialitate ale MS, prin adresa NB4469/2015* si AIT44934/2015 | DECIZIE AMNDM DE INCLUDERE CONDITION ATA NR./DATA | DATA TRANSMITERII DE ANMDM A DECIZIEI LA CNAS | MEDICAMENT DCI | MEDICAMENT DENUMIRE COMERCIALA | FORMA FARMACEUTICA | CONCENTRATIE |
|----------|---|---|---|---|----------------|--------------------------------|------------------------------|----------------|
| 11 | UCB PHARMA SA | 100 (comisia reumatologie) | 322 / 20.04.2015 | 28.04.2015 | CERTOLIZUMABUM | CIMZIA | SOL. INJ. SERINGA PREUMPLUTA | 200 mg |
| 12 | PFIZER LIMITED | 280 (comisia oncologie) | 346 / 20.04.2015 | 28.04.2015 | CRIZOTINIBUM | XALKORI | CAPSULE | 200 mg; 250 mg |
| 13 | GLAXOSMITHKLINE TRADING SERVICES LTD/NOVARTIS EUROPHARM LIMITED | 350 din care 175 alocati specific acestui medicament de comisia oncologie | 324 / 20.04.2015 | 28.04.2015 | DABRAFENIBUM | TAFINLAR | CAPSULE | 50 mg; 75 mg |
| 14 | BRISTOL - MYERS SQUIBB PHARMA EEIG | 5000 (comisia gastroenterologie) | 365 / 24.04.2015 | 28.04.2015 | DACLATASVIRUM | DAKLINZA | COMP. FILM. | 30 mg,60 mg |
| 15 | ABBVIE LTD | 5000 (comisia gastroenterologie) | 375 / 30.04.2015 | 06.05.2015 | DASABUVIRUM | EXVIERA | COMP. FILM. | 250 mg |
| 16 | GLAXOSMITHKLINE TRADING SERVICES LTD/NOVARTIS EUROPHARM LIMITED | 30 (comisia hematologie) | 323 / 20.04.2015 | 28.04.2015 | ELTROMBOPAG | REVOLADE | COMP. FILM. | 25 mg; 50mg |
| 17 | ASTELLAS PHARMA EUROPE BV | 1100 din care 550 alocati specific acestui medicament de comisia oncologie | 347 / 20.04.2015 | 28.04.2015 | ENZALUTAMIDUM | XTANDI | CAPSULE MOI | 40 mg |
| 18 | NOVARTIS EUROFARM LTD. | | 317 / 20.04.2015 | 28.04.2015 | FINGOLIMODUM | GILENYA | CAPSULE | 0,5 mg |
| 19 | BRISTOL - MYERS SQUIBB EEIG | 700 (comisia oncologie) | 313 / 20.04.2015 | 28.04.2015 | IPILIMUMAB | YERVOY | CONCENTRAT PT. SOL. PERF. | 5 mg/ml |
| 20 | GLAXO GROUP LTD/NOVARTIS EUROPHARM LIMITED | 500 (comisia oncologie) | 336 / 20.04.2015 | 28.04.2015 | LAPATINIBUM | TYVERB | COMP. | 250 mg |

| Nr. crt. | DAPP | NR PAC ELIGIBILI comunicat de comisiile de specialitate ale MS, prin adresa NB4469/2015* si AIT44934/2015 | DECIZIE AMNDM DE INCLUDERE CONDITION ATA NR./DATA | DATA TRANSMITERII DE ANMDM A DECIZIEI LA CNAS | MEDICAMENT DCI | MEDICAMENT DENUMIRE COMERCIALA | FORMA FARMACEUTICA | CONCENTRATIE |
|----------|---|---|---|---|---|--------------------------------|---------------------------|------------------------------|
| 21 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | | 328 / 20.04.2015 | 28.04.2015 | LINAGLIPTINUM | TRAJENTA | COMP. FILM. | 5 mg |
| 22 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | | 329 / 20.04.2015 | 28.04.2015 | LINAGLIPTINUM | TRAJENTA | COMP. FILM. | 5 mg |
| 23 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | | 340 / 20.04.2015 | 28.04.2015 | LINAGLIPTINUM + METFORMINUM | JENTADUETO | COMP. FILM. | 2,5 mg/850 mg; 2,5 mg/100 mg |
| 24 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | | 339 / 20.04.2015 | 28.04.2015 | LINAGLIPTINUM + METFORMINUM | JENTADUETO | COMP. FILM. | 2,5 mg/850 mg; 2,5 mg/100 mg |
| 25 | SANOFI - AVENTIS GROUPE | | 350 / 20.04.2015 | 28.04.2015 | LIXISENATIDUM | LYXUMIA | SOL. INJ. (PEN) | 10 µg, 20 µg |
| 26 | ABBVIE LTD | 5000 (comisia gastroenterologie) | 367 / 20.04.2015 | 28.04.2015 | OMBITASVIRUM + PARITAPREVIRUM + RITONAVIRUM | VIEKIRAX | COMP. FILM. | 12,5 mg; 75 mg; 50 mg |
| 27 | AMGEN EUROPE BV | 500 (comisia oncologie) | 337 / 20.04.2015 | 28.04.2015 | PANITUMUMAB | VECTIBIX | CONCENTRAT PT. SOL. PERF. | 20 mg/ml |
| 28 | GLAXO GROUP LTD/ NOVARTIS EUROPHARM LIMITED | 450 (comisia oncologie) | 325 / 20.04.2015 | 28.04.2015 | PAZOPANIB | VOTRIENT | COMP. FILM. | 200 mg; 400 mg |
| 29 | GLAXO GROUP LTD/ NOVARTIS EUROPHARM LIMITED | 200 (comisia oncologie) | 326 / 20.04.2015 | 28.04.2015 | PAZOPANIB | VOTRIENT | COMP. FILM. | 200 mg; 400 mg |

| Nr. crt. | DAPP | NR PAC ELIGIBILI comunicat de comisiile de specialitate ale MS, prin adresa NB4469/2015* si AIT44934/2015 | DECIZIE AMNDM DE INCLUDERE CONDITIONATA NR./DATA | DATA TRANSMITERII DE ANMDM A DECIZIEI LA CNAS | MEDICAMENT DCI | MEDICAMENT DENUMIRE COMERCIALA | FORMA FARMACEUTICA | CONCENTRATIE |
|----------|---|---|--|---|------------------------------|--------------------------------|--------------------|-----------------------------|
| 30 | JANSSEN CILAG INTERNATIONAL NV | 0(comisia de boli infectioase) | 333 / 20.04.2015 | 28.04.2015 | RILPIVIRINUM | EDURANT | COMP. FILM. | 25 mg |
| 31 | BAYER PHARMA AG | | 330 / 20.04.2015 | 28.04.2015 | RIVAROXABAN | XARELTO | COMP. FILM. | 15 mg; 20 mg |
| 32 | BAYER PHARMA AG | | 331 / 20.04.2015 | 28.04.2015 | RIVAROXABAN | XARELTO | COMP. FILM. | 15 mg; 20 mg |
| 33 | JANSSEN CILAG INTERNATIONAL NV - BELGIA | 5000 (comisia gastroenterologie) | 381 / 04.05.2015 | 06.05.2015 | SIMEPREVIRUM | OLYSIO | CAPSULE | 150 mg |
| 34 | GILEAD SCIENCE INTERNATIONAL LTD | 5000 (comisia gastroenterologie) | 366 / 20.04.2015 | 28.04.2015 | SOFOSUVIRUM | SOVALDI | COMP. FILM. | 400 mg |
| 35 | ASTRAZENECA AB | | 307 / 20.04.2015 | 28.04.2015 | TICAGRELORUM | BRILIQUE | COMP. FILM. | 90 mg |
| 36 | ROCHE REGISTRATION LTD | 350 din care 175 alocati specific acestui medicament de comisia oncologie | 309 / 20.04.2015 | 06.05.2015 | VEMURAFENIBUM | ZELBORAF | COMP. FILM. | 24 mg |
| 37 | NOVARTIS EUROFARM LTD. | | 316 / 20.04.2015 | 28.04.2015 | VILDAGLIPTINUM | GALVUS | COMP. | 50 mg |
| 38 | NOVARTIS EUROFARM LTD. | | 315 / 20.04.2015 | 28.04.2015 | VILDAGLIPTINUM + METFORMINUM | EUCREAS | COMP. FILM. | 50 mg/1000 mg; 50 mg/850 mg |

* Nota Datele urmeaza a fi completate pe masura ce comisiile de specialitate ale Ministerului Sanatatii vor comunica numarul de pacienti eligibili pentru fiecare arie terapeutica aferenta medicamentelor pentru care s-a emis deciziei de includere conditionata in Lista si pentru care DAPP si-au exprimat intentia de intra in procesul de negociere a contractelor cost volum/cost volum rezultat - situatie actualizata la data de 31.08.2015